Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Dose-Escalation Study of MEDI-545 in Japanese Patients With Systemic Lupus Erythematosus
jRCT2080220984Phase 2
- Sponsor
- AstraZeneca
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sifalimumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca.
02
Drugs
sifalimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080220984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220984.